These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 25296164)

  • 1. Operator dependent choice of prostate cancer biopsy has limited impact on a gene signature analysis for the highly expressed genes IGFBP3 and F3 in prostate cancer epithelial cells.
    Peng Z; Andersson K; Lindholm J; Bodin I; Pramana S; Pawitan Y; Nistér M; Nilsson S; Li C
    PLoS One; 2014; 9(10):e109610. PubMed ID: 25296164
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improving the Prediction of Prostate Cancer Overall Survival by Supplementing Readily Available Clinical Data with Gene Expression Levels of IGFBP3 and F3 in Formalin-Fixed Paraffin Embedded Core Needle Biopsy Material.
    Peng Z; Andersson K; Lindholm J; Dethlefsen O; Pramana S; Pawitan Y; Nistér M; Nilsson S; Li C
    PLoS One; 2016; 11(1):e0145545. PubMed ID: 26731648
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development and Validation of a Deep Learning Algorithm for Gleason Grading of Prostate Cancer From Biopsy Specimens.
    Nagpal K; Foote D; Tan F; Liu Y; Chen PC; Steiner DF; Manoj N; Olson N; Smith JL; Mohtashamian A; Peterson B; Amin MB; Evans AJ; Sweet JW; Cheung C; van der Kwast T; Sangoi AR; Zhou M; Allan R; Humphrey PA; Hipp JD; Gadepalli K; Corrado GS; Peng LH; Stumpe MC; Mermel CH
    JAMA Oncol; 2020 Sep; 6(9):1372-1380. PubMed ID: 32701148
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Application of a Clinical Whole-Transcriptome Assay for Staging and Prognosis of Prostate Cancer Diagnosed in Needle Core Biopsy Specimens.
    Knudsen BS; Kim HL; Erho N; Shin H; Alshalalfa M; Lam LLC; Tenggara I; Chadwich K; Van Der Kwast T; Fleshner N; Davicioni E; Carroll PR; Cooperberg MR; Chan JM; Simko JP
    J Mol Diagn; 2016 May; 18(3):395-406. PubMed ID: 26945428
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcome of Gleason 3 + 5 = 8 Prostate Cancer Diagnosed on Needle Biopsy: Prognostic Comparison with Gleason 4 + 4 = 8.
    Harding-Jackson N; Kryvenko ON; Whittington EE; Eastwood DC; Tjionas GA; Jorda M; Iczkowski KA
    J Urol; 2016 Oct; 196(4):1076-81. PubMed ID: 27265220
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An expression signature at diagnosis to estimate prostate cancer patients' overall survival.
    Peng Z; Skoog L; Hellborg H; Jonstam G; Wingmo IL; Hjälm-Eriksson M; Harmenberg U; Cedermark GC; Andersson K; Ahrlund-Richter L; Pramana S; Pawitan Y; Nistér M; Nilsson S; Li C
    Prostate Cancer Prostatic Dis; 2014 Mar; 17(1):81-90. PubMed ID: 24394557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The expression profile and heterogeneity analysis of ERG in 633 consecutive prostate cancers from a single center.
    Nie L; Pan X; Zhang M; Yin X; Gong J; Chen X; Xu M; Zhou Q; Chen N
    Prostate; 2019 Jun; 79(8):819-825. PubMed ID: 30900303
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transcriptome Wide Analysis of Magnetic Resonance Imaging-targeted Biopsy and Matching Surgical Specimens from High-risk Prostate Cancer Patients Treated with Radical Prostatectomy: The Target Must Be Hit.
    Radtke JP; Takhar M; Bonekamp D; Kesch C; Erho N; du Plessis M; Buerki C; Ong K; Davicioni E; Hohenfellner M; Hadaschik BA
    Eur Urol Focus; 2018 Jul; 4(4):540-546. PubMed ID: 28753844
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of histological findings obtained combining US/mp-MRI fusion-guided biopsies with systematic US biopsies: mp-MRI role in prostate cancer detection and false negative.
    Faiella E; Santucci D; Greco F; Frauenfelder G; Giacobbe V; Muto G; Zobel BB; Grasso RF
    Radiol Med; 2018 Feb; 123(2):143-152. PubMed ID: 29019021
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In silico mining identifies IGFBP3 as a novel target of methylation in prostate cancer.
    Perry AS; Loftus B; Moroose R; Lynch TH; Hollywood D; Watson RW; Woodson K; Lawler M
    Br J Cancer; 2007 May; 96(10):1587-94. PubMed ID: 17453001
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostate-specific antigen vs prostate-specific antigen density as a predictor of upgrading in men diagnosed with Gleason 6 prostate cancer by contemporary multicore prostate biopsy.
    Oh JJ; Hong SK; Lee JK; Lee BK; Lee S; Kwon OS; Byun SS; Lee SE
    BJU Int; 2012 Dec; 110(11 Pt B):E494-9. PubMed ID: 22540236
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-time diagnosis and Gleason grading of prostate core needle biopsies using nonlinear microscopy.
    Cahill LC; Rosen S; Yoshitake T; Wu Y; York L; Tsai LL; Gershman B; Fujimoto JG; Sun Y
    Mod Pathol; 2022 Apr; 35(4):539-548. PubMed ID: 34725447
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Length of prostate biopsy cores: does it impact cancer detection?
    Fiset PO; Aprikian A; Brimo F
    Can J Urol; 2013 Aug; 20(4):6848-53. PubMed ID: 23930611
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of gene expression in prostate cancer epithelial and interstitial stromal cells using laser capture microdissection.
    Gregg JL; Brown KE; Mintz EM; Piontkivska H; Fraizer GC
    BMC Cancer; 2010 Apr; 10():165. PubMed ID: 20426842
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Formamide as a denaturant for bisulfite conversion of genomic DNA: Bisulfite sequencing of the GSTPi and RARbeta2 genes of 43 formalin-fixed paraffin-embedded prostate cancer specimens.
    Zon G; Barker MA; Kaur P; Groshen S; Jones LW; Imam SA; Boyd VL
    Anal Biochem; 2009 Sep; 392(2):117-25. PubMed ID: 19505431
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gleason underestimation is predicted by prostate biopsy core length.
    Reis LO; Sanches BC; de Mendonça GB; Silva DM; Aguiar T; Menezes OP; Billis A
    World J Urol; 2015 Jun; 33(6):821-6. PubMed ID: 25084976
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcomes of Gleason score 3 + 4 = 7 prostate cancer with minimal amounts (<6%) vs ≥6% of Gleason pattern 4 tissue in needle biopsy specimens.
    Kır G; Seneldir H; Gumus E
    Ann Diagn Pathol; 2016 Feb; 20():48-51. PubMed ID: 26750655
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimization of initial prostate biopsy in clinical practice: sampling, labeling and specimen processing.
    Bjurlin MA; Carter HB; Schellhammer P; Cookson MS; Gomella LG; Troyer D; Wheeler TM; Schlossberg S; Penson DF; Taneja SS
    J Urol; 2013 Jun; 189(6):2039-46. PubMed ID: 23485507
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adenocarcinoma of the prostate with Gleason pattern 5 on core biopsy: frequency of diagnosis, morphologic subpatterns, and relation to pattern distribution based on the modified Gleason grading system.
    Shah RB; Tadros Y
    Hum Pathol; 2014 Nov; 45(11):2263-9. PubMed ID: 25228336
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Magnetic resonance imaging/ultrasound-fusion biopsy significantly upgrades prostate cancer versus systematic 12-core transrectal ultrasound biopsy.
    Siddiqui MM; Rais-Bahrami S; Truong H; Stamatakis L; Vourganti S; Nix J; Hoang AN; Walton-Diaz A; Shuch B; Weintraub M; Kruecker J; Amalou H; Turkbey B; Merino MJ; Choyke PL; Wood BJ; Pinto PA
    Eur Urol; 2013 Nov; 64(5):713-719. PubMed ID: 23787357
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.